48 related articles for article (PubMed ID: 15229844)
1. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
Shiefa S; Amargandhi M; Bhupendra J; Moulali S; Kristine T
Indian J Clin Biochem; 2013 Jan; 28(1):3-12. PubMed ID: 24381414
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of early morphological ultrasound in association with cell-free DNA testing in case of atypical serum markers in first trimester of pregnancy: A retrospective study over 5 years.
Claudel N; Anselem O; Buron-Fouque C; Khattabi LE; Laguillier-Morizot C; Jordan P; Tsatsaris V; Guibourdenche J; Athiel Y
J Gynecol Obstet Hum Reprod; 2024 Apr; 53(4):102745. PubMed ID: 38367703
[TBL] [Abstract][Full Text] [Related]
3. First trimester screening using ultrasound and serum markers in Panamanians: Factors associated with adverse pregnancy outcomes.
Herrera TT; Sinisterra S; Solis A; Britton GB
J Res Med Sci; 2014 May; 19(5):451-6. PubMed ID: 25097629
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different blood collection, sample matrix, and immunoassay methods in a prenatal screening setting.
Pennings JL; Siljee JE; Imholz S; Kuc S; de Vries A; Schielen PC; Rodenburg W
Dis Markers; 2014; 2014():509821. PubMed ID: 25132703
[TBL] [Abstract][Full Text] [Related]
5. Digynic monoandric triploidy in the setting of recurrent pregnancy loss: a case report and literature review.
Raymond C; Han S; Huang G; Clement C; Thaker H; Dong J
Lab Med; 2024 Jan; 55(1):103-105. PubMed ID: 37184333
[TBL] [Abstract][Full Text] [Related]
6. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
7. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
[TBL] [Abstract][Full Text] [Related]
8. The use of free beta-hCG in antenatal screening for Down's syndrome.
Wald N; Densem J; Stone R; Cheng R
Br J Obstet Gynaecol; 1993 Jun; 100(6):550-7. PubMed ID: 7687460
[TBL] [Abstract][Full Text] [Related]
9. First Trimester Screening Tests Pregnancy and Trisomy 13 Syndrome, Sex Chromosome Aneuploidy in Iran: A Cross-Sectional Study.
Harfsheno M; Barati M; Roohandeh A
Int J Fertil Steril; 2023 Jan; 17(1):34-39. PubMed ID: 36617200
[TBL] [Abstract][Full Text] [Related]
10. The Relationship between Screening Markers in the First Trimester of Pregnancy and Chromosome Aberrations.
Mirsafaie M; Moghaddam-Banaem L; Kheirollahi M
Int J Prev Med; 2022; 13():81. PubMed ID: 35706851
[TBL] [Abstract][Full Text] [Related]
11. Prenatal sonographic features can accurately determine parental origin in triploid pregnancies.
Lugthart MA; Horenblas J; Kleinrouweler EC; Engels M; Knegt AC; Huijsdens K; van Leeuwen E; Pajkrt E
Prenat Diagn; 2020 May; 40(6):705-714. PubMed ID: 32039494
[TBL] [Abstract][Full Text] [Related]
12. Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA.
McKanna T; Ryan A; Krinshpun S; Kareht S; Marchand K; Grabarits C; Ali M; McElheny A; Gardiner K; LeChien K; Hsu M; Saltzman D; Stosic M; Martin K; Benn P
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):73-79. PubMed ID: 30014528
[TBL] [Abstract][Full Text] [Related]
13. A case of triploidy detected by crosstrimester test.
Guanciali-Franchi P; Iezzi I; Matarrelli B; Morizio E; Calabrese G; Palka G
J Prenat Med; 2012 Jul; 6(3):55-6. PubMed ID: 23181174
[TBL] [Abstract][Full Text] [Related]
14. First-trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A can detect triploidy and determine the parental origin.
Yaron Y; Ochshorn Y; Tsabari S; Shira AB
Prenat Diagn; 2004 Jun; 24(6):445-50. PubMed ID: 15229844
[TBL] [Abstract][Full Text] [Related]
15. Detection of triploidy at 11-14 weeks' gestation: a cohort study of 198 000 pregnant women.
Engelbrechtsen L; Brøndum-Nielsen K; Ekelund C; Tabor A; Skibsted L;
Ultrasound Obstet Gynecol; 2013 Nov; 42(5):530-5. PubMed ID: 23494847
[TBL] [Abstract][Full Text] [Related]
16. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
17. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K; Liao AW; Skentou H; Cicero S; Nicolaides KH
Prenat Diagn; 2000 Jun; 20(6):495-9. PubMed ID: 10861716
[TBL] [Abstract][Full Text] [Related]
18. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
[TBL] [Abstract][Full Text] [Related]
19. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML; Snijders RJ; Butler J; Bersinger NA; Nicolaides KH
Br J Obstet Gynaecol; 1995 Feb; 102(2):127-32. PubMed ID: 7538782
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
